EGFR and osteosarcoma: Since MYLK4 promotes the OS progress via the EGFR signal pathway, we attempt to combine the MYLK4 inhibitor with the EGFR inhibitor in order to see whether this combination synergistically inhibits the growth and metastasis of osteosarcoma in vitro and in vivo.